ArticleClinical drug investigation2023

Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis.

Mark T Brown et al.PubMed ↗Publisher ↗

No numbers read from the abstract.